

## **REMARKS**

### ***Statement of Substance of Interview Under 37 C.F.R. § 1.133(b)***

In accordance with 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04, Applicants herein provide a summary of the interview between Applicants' representatives and Examiners Berch and Moore conducted on January 4, 2007 ("the interview"). Applicants thank Examiners Berch and Moore for agreeing to conduct the interview and appreciate the courtesies extended by the Examiners.

During the interview, Applicants' representatives discussed the rejections set forth in the Office Action. A summation of the discussion for each rejection is set forth below.

Regarding the 112, 2<sup>nd</sup> paragraph rejection, Applicants' representatives asserted that one of skill in the art would understand that term "PDE7" encompasses all PDE7 isoforms. To further support this assertion, Applicants' representatives presented the Examiners with U.S. Patent No. 6,617,357 ("the '357 patent"). The '357 patent states that two sub-types of PDE7 have been identified — PDE7A and PDE7B — and are referred to collectively as "PDE7." See e.g., col. 1, lines 22-32. The Examiners agreed that the 112, 2<sup>nd</sup> paragraph rejection over "PDE7" would be withdrawn in view of the '357 patent.

Regarding the 112, 1<sup>st</sup> paragraph rejection, Applicants' representatives discussed the possibility of submitting a declaration that shows the selectivity of PDE7 and/or the suppression of T-cell activation.

Regarding the 103(a) rejections over U.S. Patent Nos. 6,677,335 ("the '335 patent") and 6,407,114 ("the '114 patent"), Applicants' representatives discussed the possibility of submitting a declaration comparing the claimed compounds and those cited by the Examiner (i.e., the compound of Example 82 in the '335 patent and the compounds of Examples 25 and 55 in the '114 patent).

The parties did not discuss the provisional obviousness-type double patenting rejection.

**CONCLUSION**


It is believed that no additional fees are required for entry of this response. However, should any fees be necessary to enter this paper or maintain the pendency of this application, the Commissioner is authorized to charge such fees to **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS, LLP

Dated: May 14, 2007

By:



Robert M. Schulman  
Registration No. 31,196

Alexander H. Spiegler  
Registration No. 56,625

HUNTON & WILLIAMS LLP  
Intellectual Property Department  
1900 K Street, N.W. Suite 1200  
Washington, DC 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)

RMS/AHS:sac